Taiho Pharma launches HSP90 inhibitor Jeselhy

31 August 2022

Taiho Pharmaceutical, a subsidiary of Japanese drugmaker Otsuka Holdings (TYO: 4578), says it has launched the oral heat shock protein (HSP) 90 inhibitor Jeselhy (pimitespib) tablets 40mg in Japan.

Jeselhy, a compound discovered by Taiho Pharmaceutical, inhibits HSP90, thereby showing an antitumor effect by destabilizing and reducing proteins such as KIT, PDGFRA, HER2, and EGFR which are involved in the growth and survival of cancer.

Based on the results of a Phase III trial (CHAPTER-GIST-301 trial) comparing the efficacy and safety of Jeselhy versus placebo in patients with previously treated gastrointestinal stromal tumor (GIST), Jeselhy received manufacturing and marketing approval in June for the indication of GIST that has progressed after chemotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK